The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

“We are advancing our SERENITY At-Home trial to pursue the near-term growth opportunity for treating acute agitation associated with bipolar disorders or schizophrenia in the outpatient setting. At ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

Chronic inflammation has been shown to negatively affect the whole body, from cognition to joint health. Despite these ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

Sonoma County is among 50 counties due to implement CARE Court by Dec. 1. The program is meant to address the state’s most ...

Recently approved xanomeline and trospium chloride (Cobenfy) demonstrated long-term efficacy and safety in patients with ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

(RTTNews) - Intra-Cellular Therapies, Inc. (ITCI), Tuesday announced positive data from phase 3 trial of Lumateperone, marketed as Caplyta, for the prevention of relapse in adult patients with ...